Methods We did a randomised, double-blind, parallel-group, phase 3, non-inferiority trial in 76 centres in 17 countries in Asia, Europe, and the USA (APEKS-NP). We enrolled adults aged 18 years and older with hospital-acquired, ventilator-associated, or health-care-associated Gram-negative...
These differences in rates of cefiderocol HR correlated with the mortality data from the APEKS-NP and CREDIBLE-CR trials, across the bacterial species tested (Table). Table: Surveillance rates of cefiderocol heteroresistance correlate with all-cause mortality in the APEKS-NP and CREDIBLE-CR ...
Clinicaltrials.gov: APEKS-NP: NCT03032380; CREDIBLE-CR: NCT02714595.Patrice NordmannRyan K. ShieldsYohei DoiMiki TakemuraRoger EcholsYuko MatsunagaYoshinori YamanoMicrobial Drug Tesistance:Mechanisms,Epidemiology and Disease(631B0162)
Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?doi:10.1016/S2666-5247(21)00271-8Jacob E.ChobyEmory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA.Tugba.Ozturk...